Jespersen C M, Klitgaard N A, Nielsen H, Hansen J F
Medical Department, Københavns Kommunehospital, Copenhagen, Denmark.
Eur J Clin Pharmacol. 1989;36(6):625-7. doi: 10.1007/BF00637748.
The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations. The diurnal serum concentrations of verapamil and norverapamil did not differ significantly during treatment with verapamil-IR 120 mg t.i.d. and verapamil-SR 360 mg once daily, but verapamil-SR 240 mg produced significantly lower serum concentrations. The differences did not affect the exercise capacity or the occurrence of ST-segment depression during maximal exercise. Verapamil-SR was well tolerated. A multiple instant-release dosage regime can now be replaced by once daily administration of the sustained-release preparation.
在10例稳定型心绞痛患者中,对维拉帕米缓释制剂(维拉帕米-SR)和传统速释制剂(维拉帕米-IR)的疗效进行了比较。这两种制剂均对患者进行了为期3周的治疗。在使用维拉帕米-IR每日3次、每次120mg以及维拉帕米-SR每日1次、每次360mg治疗期间,维拉帕米和去甲维拉帕米的日间血清浓度无显著差异,但维拉帕米-SR 240mg产生的血清浓度显著较低。这些差异并未影响运动能力或最大运动时ST段压低的发生情况。维拉帕米-SR耐受性良好。现在,多次速释给药方案可以被缓释制剂的每日一次给药所取代。